NCT02077569已完成2 期
The Short Term Effects of an AKT Inhibitor (AZD5363) on Biomarkers of the AKT Pathway and Anti-tumour Activity in a Breast Cancer Paired Biopsy Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 11
- 主要终点
- Primary endpoint: Pharmacodynamic biomarker analysis in tumour tissue to assess the biological effect of AZD5363 on markers of anti-proliferation and the AKT pathway
研究概览
简要总结
To compare the effect of four and a half days treatment of a range of doses of AZD5363 on selected markers of the AKT pathway and anti-proliferation compared with placebo in oestrogen receptor positive breast cancers.
To assess the tolerability of four and a half days treatment of AZD5363.
详细描述
The principal research questions to be addressed are whether (or not) AZD5363 is "hitting its therapeutic target" sufficiently and to the extent that is required to produce efficacy in pre-clinical experiments.
The primary endpoint markers have been selected to determine this.
Reductions in markers of the AKT pathway and increases in markers of anti-proliferation will characterise the degree of biological activity arising from the inhibition of AKT across a range of doses of AZD5363.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •WHO performance status 0-
- •Able to swallow & retain oral medication.
- •Patients who fall in to either category (a) or (b):
- •Post-menopausal patients
- •Pre-menopausal patients who also meet at least one of the criteria (i), (ii) or (iii) below:
- •i) hysterectomy or bilateral fallopian tube ligation at least 6 weeks ago plus a negative pregnancy test.
- •ii) true abstinence iii) willing to have pregnancy testing and use 2 forms of contraception
- •Female patients, aged 18 years and over, with histological confirmation of ER positive invasive breast carcinoma.
- •Stage 1/2/3 or Stage 4 with primary tumour in the breast amenable to biopsies. New primary breast tumours (ipsi- or contra-lateral) despite prior endocrine treatment for an earlier primary breast tumour with at least 12 months interval between cessation of endocrine therapy and Visit 1 are eligible.
- •Scheduled to have chemotherapy based on tumour characteristics and local treatment protocols.
- •Tumours large enough to provide sufficient tissue to be taken by core-cut or tru-cut biopsy to provide tissue sections for the marker assays.
排除标准
- •Prior treatment for breast cancer except new primary breast tumours arising despote prior endocrine treatment for an earlier primary breas tumour with at least 12 months interval between cessation of endocrine therapy and Visit 1 (see inclusion criteria 6).
- •Known ER negative tumour.
- •Female patients with histological confirmation of ER+ve invasive breast carcinoma not scheduled to have chemotherapy
- •Exposure to potent inhibitors or inducers of CYP3A4 or CYP2D6 or substrates of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St Johns Wort).
- •Clinically significant abnormalities of glucose metabolism
- •Major surgery (excluding placement of vascular access) within 4 weeks before the first dose of study treatment.
- •Spinal cord compression or brain metastases.
- •Evidence of severe or uncontrolled systemic disease.
- •Any of the following cardiac criteria:
- •Mean resting corrected QT interval (QTc)>450 msec obtained from 3 consecutive ECGs; - Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG
- •Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
- •Any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA Grade
- •Uncontrolled hypotension.
- •Absolute neutrophil count <1.5 x 10,000,000,000/L
- •Platelet count <100 x 10,000,000,000/L.
- •Haemoglobin <90 g/L
- •ALT >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases.
- •Elevated ALP is not exclusionary if due to the presence of bone metastasis and liver function is otherwise considered adequate
- •Total bilirubin >1.5 times ULN if no liver metastases or >3 times ULN in the presence of liver metastases.
- •Creatinine >1.5 times ULN concurrent with creatinine clearance <50 ml/min; confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN
- •Proteinuria >3+ on dipstick analysis.
- •Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD
- •History of hypersensitivity to active or inactive excipients of AZD5363 or drugs with a similar chemical structure or class to AZD
- •Current disease or condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
- •Past medical history of interstitial lung disease, drug induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
- •Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent
- •Previous allogeneic bone marrow transplant.
- •Known immunodeficiency syndrome.
- •Pregnant or lactating patients
研究组 & 干预措施
AZD5363 480mg
Experimental
STAGE 1 ONLY AZD5363 480mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
干预措施: AZD5363 (Drug)
Placebo
Placebo Comparator
STAGE 1 ONLY Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
干预措施: AZD5363 (Drug)
AZD360mg
Experimental
STAGE 2 AZD5363 360mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
干预措施: AZD5363 (Drug)
AZD5363 240mg
Experimental
STAGE 2 AZD5363 240mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
干预措施: AZD5363 (Drug)
结局指标
主要结局
Primary endpoint: Pharmacodynamic biomarker analysis in tumour tissue to assess the biological effect of AZD5363 on markers of anti-proliferation and the AKT pathway
时间窗: Up to 42 months: Stage 1: up to 60 participants in up to 20 months. Stage 1 biomarker analysis early in Stage 2. Stage 2 proceeds where reduction in 1 of the 3 primary biomarkers. Stage 2: up to 60 participants in up to 16 months.
Changes in pPRAS40, pGSK3b, Ki67
次要结局
- Compare anti-proliferative effect on markers of the AKT pathway after 4&1/2days treatment at 3 different doses of AZD5363 vs placebo in Er +ve breast cancers(Up to 42 months. Stage 1: up to 60 participants in up to 20 months. Stage 2: up to 60 participants in up to 16 months.)
- Compare direct effect on markers of the AKT pathway after 4&1/2days treatment at 3 different doses of AZD5363 vs placebo in Er +ve breast cancers(Up to 42 months. Stage 1: up to 60 participants in up to 20 months. Stage 2: up to 60 participants in up to 16 months.)
- To measure tolerability and toxicity following short term (four and a half days) exposure to AZD5363(Up to 42 months. Stage 1: up to 60 participants in up to 20 months. Stage 2: up to 60 participants in up to 16 months.)
研究者
研究点 (11)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to investigate the safety and effectiveness of a new anti cancer treatment - AZD5363 and assess its ability to affect levels of key proteins in cancer cells prior to the surgical removal of breast cancer.primary breast cancerMedDRA version: 18.1 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005019-14-GBniversity of Nottingham48
已完成
1 期
Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP ChemotherapyProstate CancerNCT02121639University Hospital Southampton NHS Foundation Trust160
已完成
1 期
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus PatientsType 2 Diabetes MellitusNCT01103622AstraZeneca20
已完成
1 期
A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718Coronary Artery DiseaseNCT04087187AstraZeneca14
已完成
1 期
Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT01082120AstraZeneca28